FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226410464> ?p ?o ?g. }

• W4226410464 endingPage "251" @default.
• W4226410464 startingPage "241" @default.
• W4226410464 abstract "Objective: Adolescent depression is prevalent and is associated with significant morbidity and mortality. Although intravenous ketamine has shown efficacy in adult treatment-resistant depression, its efficacy in pediatric populations is unknown. The authors conducted an active-placebo-controlled study of ketamine’s safety and efficacy in adolescents. Methods: In this proof-of-concept randomized, double-blind, single-dose crossover clinical trial, 17 adolescents (ages 13–17) with a diagnosis of major depressive disorder received a single intravenous infusion of either ketamine (0.5 mg/kg over 40 minutes) or midazolam (0.045 mg/kg over 40 minutes), and the alternate compound 2 weeks later. All participants had previously tried at least one antidepressant medication and met the severity criterion of a score >40 on the Children’s Depression Rating Scale–Revised. The primary outcome measure was score on the Montgomery-Åsberg Depression Rating Scale (MADRS) 24 hours after treatment. Results: A single ketamine infusion significantly reduced depressive symptoms 24 hours after infusion compared with midazolam (MADRS score: midazolam, mean=24.13, SD=12.08, 95% CI=18.21, 30.04; ketamine, mean=15.44, SD=10.07, 95% CI=10.51, 20.37; mean difference=−8.69, SD=15.08, 95% CI=−16.72, −0.65, df=15; effect size=0.78). In secondary analyses, the treatment gains associated with ketamine appeared to remain 14 days after treatment, the latest time point assessed, as measured by the MADRS (but not as measured by the Children’s Depression Rating Scale–Revised). A significantly greater proportion of participants experienced a response to ketamine during the first 3 days following infusion as compared with midazolam (76% and 35%, respectively). Ketamine was associated with transient, self-limited dissociative symptoms that affected participant blinding, but there were no serious adverse events. Conclusions: In this first randomized placebo-controlled clinical trial of intravenous ketamine in adolescents with depression, the findings suggest that it is well tolerated acutely and has significant short-term (2-week) efficacy in reducing depressive symptoms compared with an active placebo. Reprinted from Am J Psychiatry 2021; 178:352–362 with permission from American Psychiatric Association Publishing." @default.
• W4226410464 created "2022-05-05" @default.
• W4226410464 creator A5037185919 @default.
• W4226410464 creator A5037459959 @default.
• W4226410464 creator A5043592614 @default.
• W4226410464 creator A5046570333 @default.
• W4226410464 creator A5046972463 @default.
• W4226410464 creator A5059319197 @default.
• W4226410464 creator A5060512263 @default.
• W4226410464 creator A5065651419 @default.
• W4226410464 creator A5090109190 @default.
• W4226410464 date "2022-04-01" @default.
• W4226410464 modified "2023-09-30" @default.
• W4226410464 title "Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial" @default.
• W4226410464 cites W107007631 @default.
• W4226410464 cites W1493562807 @default.
• W4226410464 cites W1964466640 @default.
• W4226410464 cites W1976396510 @default.
• W4226410464 cites W1992784372 @default.
• W4226410464 cites W1998149933 @default.
• W4226410464 cites W2005846380 @default.
• W4226410464 cites W2037096268 @default.
• W4226410464 cites W2044440339 @default.
• W4226410464 cites W2054702712 @default.
• W4226410464 cites W2057880023 @default.
• W4226410464 cites W2065796254 @default.
• W4226410464 cites W2073079805 @default.
• W4226410464 cites W2084722042 @default.
• W4226410464 cites W2097857685 @default.
• W4226410464 cites W2099840408 @default.
• W4226410464 cites W2105627372 @default.
• W4226410464 cites W2111199710 @default.
• W4226410464 cites W2111728433 @default.
• W4226410464 cites W2113281483 @default.
• W4226410464 cites W2123698469 @default.
• W4226410464 cites W2131823335 @default.
• W4226410464 cites W2135632106 @default.
• W4226410464 cites W2138437831 @default.
• W4226410464 cites W2140498388 @default.
• W4226410464 cites W2160051587 @default.
• W4226410464 cites W2165399323 @default.
• W4226410464 cites W2346390990 @default.
• W4226410464 cites W2397193160 @default.
• W4226410464 cites W2416469128 @default.
• W4226410464 cites W2593791726 @default.
• W4226410464 cites W2600897611 @default.
• W4226410464 cites W2747721206 @default.
• W4226410464 cites W2789400649 @default.
• W4226410464 cites W2884469025 @default.
• W4226410464 cites W2911080671 @default.
• W4226410464 cites W2933289315 @default.
• W4226410464 cites W2935676591 @default.
• W4226410464 cites W3004998718 @default.
• W4226410464 doi "https://doi.org/10.1176/appi.focus.22020004" @default.
• W4226410464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37153136" @default.
• W4226410464 hasPublicationYear "2022" @default.
• W4226410464 type Work @default.
• W4226410464 citedByCount "5" @default.
• W4226410464 countsByYear W42264104642022 @default.
• W4226410464 countsByYear W42264104642023 @default.
• W4226410464 crossrefType "journal-article" @default.
• W4226410464 hasAuthorship W4226410464A5037185919 @default.
• W4226410464 hasAuthorship W4226410464A5037459959 @default.
• W4226410464 hasAuthorship W4226410464A5043592614 @default.
• W4226410464 hasAuthorship W4226410464A5046570333 @default.
• W4226410464 hasAuthorship W4226410464A5046972463 @default.
• W4226410464 hasAuthorship W4226410464A5059319197 @default.
• W4226410464 hasAuthorship W4226410464A5060512263 @default.
• W4226410464 hasAuthorship W4226410464A5065651419 @default.
• W4226410464 hasAuthorship W4226410464A5090109190 @default.
• W4226410464 hasBestOaLocation W42264104642 @default.
• W4226410464 hasConcept C126322002 @default.
• W4226410464 hasConcept C138496976 @default.
• W4226410464 hasConcept C139719470 @default.
• W4226410464 hasConcept C142724271 @default.
• W4226410464 hasConcept C15744967 @default.
• W4226410464 hasConcept C162324750 @default.
• W4226410464 hasConcept C168563851 @default.
• W4226410464 hasConcept C204787440 @default.
• W4226410464 hasConcept C27081682 @default.
• W4226410464 hasConcept C2776814716 @default.
• W4226410464 hasConcept C2776867660 @default.
• W4226410464 hasConcept C2778000748 @default.
• W4226410464 hasConcept C2779144063 @default.
• W4226410464 hasConcept C2780051608 @default.
• W4226410464 hasConcept C2780795376 @default.
• W4226410464 hasConcept C42219234 @default.
• W4226410464 hasConcept C71924100 @default.
• W4226410464 hasConcept C83849319 @default.
• W4226410464 hasConcept C87813604 @default.
• W4226410464 hasConceptScore W4226410464C126322002 @default.
• W4226410464 hasConceptScore W4226410464C138496976 @default.
• W4226410464 hasConceptScore W4226410464C139719470 @default.
• W4226410464 hasConceptScore W4226410464C142724271 @default.
• W4226410464 hasConceptScore W4226410464C15744967 @default.
• W4226410464 hasConceptScore W4226410464C162324750 @default.
• W4226410464 hasConceptScore W4226410464C168563851 @default.
• W4226410464 hasConceptScore W4226410464C204787440 @default.

• next